Masimo (MASI) Beats Q1 Earnings & Revenues; FY16 View Up

Masimo Corp (NASDAQ:MASI) reported earnings of 53 cents per share in the first quarter of 2016, which beat the Zacks Consensus Estimate by a dime and increased 39.5% on a year-over-year basis.

Quarter Details

Revenues increased 10.8% year over year to $171.2 million, which was better than the Zacks Consensus Estimate of $165 million. Product revenues improved 10.8% year over year (11.7% at constant currency) to $163.3 million, while revenues from royalty increased 9.7% to $7.9 million.

Worldwide direct product revenues (86.3% of product revenues) increased 12.7% on a year-over-year basis to $140.9 million. OEM sales (13.7% of product revenues) rose 0.2% on robust demand for sensors and licenses.

Masimo rainbow revenues advanced 39.2% (37% at cc) to $16.9 million, driven by a large order from the Middle East. SpHb revenues improved 164% to $6.1 million backed by strong demand from the region.

During the first quarter, SET pulse oximetry and rainbow Pulse CO-Oximetry unit shipments (excluding handheld units) totaled 46,300. Per Masimo, worldwide installed base as of Apr 2, 2016, stood at 1,438,000 units, up 7.3% from 1,340,000 units as of Apr 4, 2015.

U.S. product revenues increased 5.8% to $113.5 million. International product revenues increased 24.2% from the year-ago quarter to $49.8 million (up 27.6% at constant currency), driven by strong demand from the EMEA region and Japan.

Guidance

For full-year 2016, Masimo projects total revenues of $677 million, up from the earlier projection of $670 million. Product revenues are expected at around $647 million, up from the previous guidance of $640 million, while Royalty revenue projection is maintained at $30 million. Rainbow revenues are expected to cross $68 million.

Masimo forecasts gross margin of approximately 64.7%. Management expects operating expenses of approximately $312 million, down from the earlier guidance of $317 million.

Masimo now projects earnings of $1.83 per share, up from the earlier projected figure of $1.69.

Zacks Rank & Stocks to Consider

Currently, Masimo carries a Zacks Rank #3 (Hold).

Better-ranked stocks in the medical instruments industry include Edwards Lifesciences (NYSE:EW) , IRadimed (NASDAQ:IRMD) and Abiomed (NASDAQ:ABMD) . While Edwards Lifesciences and IRadimed sport a Zacks Rank #1 (Strong Buy), Abiomed carries a Zacks Rank #2 (Buy).